Cargando…

Harnessing the Medicaid Analytic eXtract (MAX) to Evaluate Medications in Pregnancy: Design Considerations

BACKGROUND: In the absence of clinical trial data, large post-marketing observational studies are essential to evaluate the safety and effectiveness of medications during pregnancy. We identified a cohort of pregnancies ending in live birth within the 2000–2007 Medicaid Analytic eXtract (MAX). Herei...

Descripción completa

Detalles Bibliográficos
Autores principales: Palmsten, Kristin, Huybrechts, Krista F., Mogun, Helen, Kowal, Mary K., Williams, Paige L., Michels, Karin B., Setoguchi, Soko, Hernández-Díaz, Sonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693950/
https://www.ncbi.nlm.nih.gov/pubmed/23840692
http://dx.doi.org/10.1371/journal.pone.0067405
_version_ 1782274778708574208
author Palmsten, Kristin
Huybrechts, Krista F.
Mogun, Helen
Kowal, Mary K.
Williams, Paige L.
Michels, Karin B.
Setoguchi, Soko
Hernández-Díaz, Sonia
author_facet Palmsten, Kristin
Huybrechts, Krista F.
Mogun, Helen
Kowal, Mary K.
Williams, Paige L.
Michels, Karin B.
Setoguchi, Soko
Hernández-Díaz, Sonia
author_sort Palmsten, Kristin
collection PubMed
description BACKGROUND: In the absence of clinical trial data, large post-marketing observational studies are essential to evaluate the safety and effectiveness of medications during pregnancy. We identified a cohort of pregnancies ending in live birth within the 2000–2007 Medicaid Analytic eXtract (MAX). Herein, we provide a blueprint to guide investigators who wish to create similar cohorts from healthcare utilization data and we describe the limitations in detail. METHODS: Among females ages 12–55, we identified pregnancies using delivery-related codes from healthcare utilization claims. We linked women with pregnancies to their offspring by state, Medicaid Case Number (family identifier) and delivery/birth dates. Then we removed inaccurate linkages and duplicate records and implemented cohort eligibility criteria (i.e., continuous and appropriate enrollment type, no private insurance, no restricted benefits) for claim information completeness. RESULTS: From 13,460,273 deliveries and 22,408,810 child observations, 6,107,572 pregnancies ending in live birth were available after linkage, cleaning, and removal of duplicate records. The percentage of linked deliveries varied greatly by state, from 0 to 96%. The cohort size was reduced to 1,248,875 pregnancies after requiring maternal eligibility criteria throughout pregnancy and to 1,173,280 pregnancies after further applying infant eligibility criteria. Ninety-one percent of women were dispensed at least one medication during pregnancy. CONCLUSIONS: Mother-infant linkage is feasible and yields a large pregnancy cohort, although the size decreases with increasing eligibility requirements. MAX is a useful resource for studying medications in pregnancy and a spectrum of maternal and infant outcomes within the indigent population of women and their infants enrolled in Medicaid. It may also be used to study maternal characteristics, the impact of Medicaid policy, and healthcare utilization during pregnancy. However, careful attention to the limitations of these data is necessary to reduce biases.
format Online
Article
Text
id pubmed-3693950
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36939502013-07-09 Harnessing the Medicaid Analytic eXtract (MAX) to Evaluate Medications in Pregnancy: Design Considerations Palmsten, Kristin Huybrechts, Krista F. Mogun, Helen Kowal, Mary K. Williams, Paige L. Michels, Karin B. Setoguchi, Soko Hernández-Díaz, Sonia PLoS One Research Article BACKGROUND: In the absence of clinical trial data, large post-marketing observational studies are essential to evaluate the safety and effectiveness of medications during pregnancy. We identified a cohort of pregnancies ending in live birth within the 2000–2007 Medicaid Analytic eXtract (MAX). Herein, we provide a blueprint to guide investigators who wish to create similar cohorts from healthcare utilization data and we describe the limitations in detail. METHODS: Among females ages 12–55, we identified pregnancies using delivery-related codes from healthcare utilization claims. We linked women with pregnancies to their offspring by state, Medicaid Case Number (family identifier) and delivery/birth dates. Then we removed inaccurate linkages and duplicate records and implemented cohort eligibility criteria (i.e., continuous and appropriate enrollment type, no private insurance, no restricted benefits) for claim information completeness. RESULTS: From 13,460,273 deliveries and 22,408,810 child observations, 6,107,572 pregnancies ending in live birth were available after linkage, cleaning, and removal of duplicate records. The percentage of linked deliveries varied greatly by state, from 0 to 96%. The cohort size was reduced to 1,248,875 pregnancies after requiring maternal eligibility criteria throughout pregnancy and to 1,173,280 pregnancies after further applying infant eligibility criteria. Ninety-one percent of women were dispensed at least one medication during pregnancy. CONCLUSIONS: Mother-infant linkage is feasible and yields a large pregnancy cohort, although the size decreases with increasing eligibility requirements. MAX is a useful resource for studying medications in pregnancy and a spectrum of maternal and infant outcomes within the indigent population of women and their infants enrolled in Medicaid. It may also be used to study maternal characteristics, the impact of Medicaid policy, and healthcare utilization during pregnancy. However, careful attention to the limitations of these data is necessary to reduce biases. Public Library of Science 2013-06-26 /pmc/articles/PMC3693950/ /pubmed/23840692 http://dx.doi.org/10.1371/journal.pone.0067405 Text en © 2013 Palmsten et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Palmsten, Kristin
Huybrechts, Krista F.
Mogun, Helen
Kowal, Mary K.
Williams, Paige L.
Michels, Karin B.
Setoguchi, Soko
Hernández-Díaz, Sonia
Harnessing the Medicaid Analytic eXtract (MAX) to Evaluate Medications in Pregnancy: Design Considerations
title Harnessing the Medicaid Analytic eXtract (MAX) to Evaluate Medications in Pregnancy: Design Considerations
title_full Harnessing the Medicaid Analytic eXtract (MAX) to Evaluate Medications in Pregnancy: Design Considerations
title_fullStr Harnessing the Medicaid Analytic eXtract (MAX) to Evaluate Medications in Pregnancy: Design Considerations
title_full_unstemmed Harnessing the Medicaid Analytic eXtract (MAX) to Evaluate Medications in Pregnancy: Design Considerations
title_short Harnessing the Medicaid Analytic eXtract (MAX) to Evaluate Medications in Pregnancy: Design Considerations
title_sort harnessing the medicaid analytic extract (max) to evaluate medications in pregnancy: design considerations
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3693950/
https://www.ncbi.nlm.nih.gov/pubmed/23840692
http://dx.doi.org/10.1371/journal.pone.0067405
work_keys_str_mv AT palmstenkristin harnessingthemedicaidanalyticextractmaxtoevaluatemedicationsinpregnancydesignconsiderations
AT huybrechtskristaf harnessingthemedicaidanalyticextractmaxtoevaluatemedicationsinpregnancydesignconsiderations
AT mogunhelen harnessingthemedicaidanalyticextractmaxtoevaluatemedicationsinpregnancydesignconsiderations
AT kowalmaryk harnessingthemedicaidanalyticextractmaxtoevaluatemedicationsinpregnancydesignconsiderations
AT williamspaigel harnessingthemedicaidanalyticextractmaxtoevaluatemedicationsinpregnancydesignconsiderations
AT michelskarinb harnessingthemedicaidanalyticextractmaxtoevaluatemedicationsinpregnancydesignconsiderations
AT setoguchisoko harnessingthemedicaidanalyticextractmaxtoevaluatemedicationsinpregnancydesignconsiderations
AT hernandezdiazsonia harnessingthemedicaidanalyticextractmaxtoevaluatemedicationsinpregnancydesignconsiderations